Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

GRI

GRI Bio Inc

Jul 26 • 04:00PM ET

1.26

Dollar change -0.01
Percentage change -0.79	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-347.34	Insider Own	1.50%	Shs Outstand	-	Perf Week	-24.55%
Market Cap	1.29M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.01M	Perf Month	-31.15%
Income	-12.77M	PEG	-	EPS next Q	-	Inst Own	1.76%	Short Float	8.31%	Perf Quarter	-77.47%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	61.16%	Short Ratio	0.21	Perf Half Y	-95.05%
Book/sh	11.38	P/B	0.11	EPS next Y	-	ROA	-382.23%	Short Interest	0.08M	Perf Year	-99.63%
Cash/sh	4.01	P/C	0.31	EPS next 5Y	-	ROE	-903.08%	52W Range	1.15 - 349.89	Perf YTD	-96.40%
Dividend Est.	-	P/FCF	-	EPS past 5Y	26.64%	ROI	-439.42%	52W High	-99.64%	Beta	-1.63
Dividend TTM	-	Quick Ratio	2.64	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	9.57%	ATR (14)	0.37
Dividend Ex-Date	-	Current Ratio	2.64	EPS Y/Y TTM	78.24%	Oper. Margin	0.00%	RSI (14)	23.94	Volatility	32.18% 18.41%
Employees	4	Debt/Eq	0.05	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	32760.00
Option/Short	No / Yes	LT Debt/Eq	0.04	EPS Q/Q	98.77%	Payout	-	Rel Volume	1.23	Prev Close	1.27
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	Apr 01 BMO	Avg Volume	407.30K	Price	1.26
SMA20	-24.60%	SMA50	-58.30%	SMA200	-95.94%	Trades		Volume	499,599	Change	-0.79%

Jul-15-24 09:05AM	GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series (GlobeNewswire)
Jul-11-24 09:20AM	GRI Bio (NASDAQ: GRI) Participates in Virtual Investor What This Means Segment (GlobeNewswire)
Jul-08-24 09:05AM	GRI Bio Regains Compliance with Nasdaq (GlobeNewswire)
Jul-02-24 09:05AM	GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine (GlobeNewswire) -13.68%
Jul-01-24 08:45AM	GRI Bio to Present at the 8th Annual IPF Summit (GlobeNewswire)
04:05PM	Loading…
Jun-28-24 04:05PM	GRI Bio Announces Closing of $4.0 Million Public Offering (GlobeNewswire)
Jun-27-24 09:00AM	GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators (GlobeNewswire) +7.10%
08:00AM	GRI Bio Announces Pricing of $4 Million Public Offering (GlobeNewswire)
Jun-26-24 08:23AM	Why Is GRI Bio (GRI) Stock Down 29% Today? (InvestorPlace) -38.38%
07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
Jun-24-24 07:16AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
Jun-17-24 08:00AM	Final Participating Company Line-Up Announced for the Virtual Investor Pitch Conference Hosted by JTC Team Being Held June 17 - 18, 2024 (ACCESSWIRE)
Jun-14-24 08:05AM	GRI Bio Announces Reverse Stock Split (GlobeNewswire) -11.90%
Jun-12-24 04:15PM	Connect Biopharma Announces New Leadership and Chair of the Board of Directors (GlobeNewswire)
Jun-11-24 09:00AM	GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor Pitch Conference (GlobeNewswire)
08:00AM	Loading…
Jun-10-24 08:00AM	JTC Team Announces Participating Company Line-Up for the Virtual Investor Pitch Conference on June 17-18, 2024 (ACCESSWIRE)
May-23-24 10:30AM	GRI Bio (NASDAQ: GRI) Participates in Virtual Investor CEO Connect (ACCESSWIRE) -9.03%
May-22-24 09:15AM	GRI Bio (NASDAQ: GRI) Participates in Virtual Investor What This Means Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs (GlobeNewswire) +9.53%
May-21-24 08:35AM	GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE) (GlobeNewswire)
May-20-24 08:45AM	GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF) (GlobeNewswire)
May-14-24 09:05AM	GRI Bio to Present at Alliance Global Partner's 2024 Healthcare Company Showcase (GlobeNewswire)
May-13-24 10:54AM	GRI Stock Earnings: GRI Bio Reported Results for Q1 2024 (InvestorPlace)
08:00AM	GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-29-24 08:45AM	GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity (GlobeNewswire)
Apr-25-24 09:15AM	GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar (GlobeNewswire)
Apr-16-24 08:35AM	GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent (GlobeNewswire)
Apr-08-24 08:35AM	GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference (GlobeNewswire) +5.16%
Apr-01-24 07:35AM	GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-28-24 09:00AM	GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference (GlobeNewswire)
Mar-14-24 08:45AM	GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators (GlobeNewswire)
08:30AM	Loading…
Mar-04-24 08:30AM	GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom (GlobeNewswire)
Feb-02-24 08:55AM	Why Is GRI Bio (GRI) Stock Down 21% Today? (InvestorPlace) -26.15%
08:00AM	GRI Bio Announces Pricing of $5.5 Million Public Offering (GlobeNewswire)
Jan-26-24 08:05AM	GRI Bio Announces Reverse Stock Split (GlobeNewswire) +5.62%
Dec-06-23 01:47PM	GRI Bio begins patent enrollment for Phase 2a study of GRI-0621 for IPF treatment (News Direct) -5.98%
Dec-05-23 09:05AM	GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis ( IPF ) (GlobeNewswire) -25.39%
Nov-27-23 08:35AM	GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT ( iNKT ) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis ( IPF ) (GlobeNewswire) -13.33%
Nov-15-23 08:05AM	GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -6.49%
Oct-31-23 08:45AM	GRI Bio Presents Data Supporting Innovative Pipeline of NKT Cell Modulators for the Treatment of High-Value Inflammatory, Fibrotic and Autoimmune Diseases (GlobeNewswire) +5.17%
Oct-19-23 08:45AM	GRI Bio Presents Translational Data Demonstrating Connection Between NKT Cells and the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung Conference (GlobeNewswire)
Oct-18-23 10:00AM	JTC Team Announces Presenting Company Line Up for the Virtual Investor Ask the CEO Conference Being Held October 24-25, 2023 (ACCESSWIRE) -5.47%
Oct-17-23 08:35AM	GRI Bio Announces Partnership with the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression (GlobeNewswire) -14.09%
Oct-11-23 09:05AM	GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Ask the CEO Conference (GlobeNewswire)
Oct-05-23 08:45AM	GRI Bio Announces Publication of Comprehensive Invariant NKT (iNKT) Cell Review in Frontiers in Immunology Demonstrating a Key Role of Type 1 iNKT Cells in Modulating Various Fibrotic Conditions (GlobeNewswire)
Sep-29-23 09:00AM	September Is Pulmonary Fibrosis Awareness Month: Heres What One Company Is Doing To Develop A Treatment For This Deadly Disease (ACCESSWIRE) -6.91%
Sep-06-23 09:05AM	GRI Bio to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Sep-01-23 09:15AM	IPF Has A 0% Survival Rate Without Lung Transplant And A Median Survival Time Of 2-5 Years From Diagnosis - Could GRI-0621 Be The Solution? (ACCESSWIRE)
Aug-29-23 11:06AM	GRI Bio Engages B2i Digital to Deploy Cutting-Edge Engagement Campaign (Newsfile) +5.74%
Aug-25-23 09:00AM	GRI Bio Is Bringing Hope To Patients With Idiopathic Pulmonary Fibrosis And Lupus (ACCESSWIRE) -12.26%
Aug-23-23 09:00AM	GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIR (GlobeNewswire) -25.75%
Aug-16-23 12:00PM	JTC Team Announces the Launch of the Virtual Investor "What This Means" On Demand Video Series (ACCESSWIRE)
Aug-14-23 08:05AM	GRI Bio (NASDAQ: GRI) Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-07-23 08:35AM	GRI Bio Presents Encouraging Preclinical Data Indicating Oral Administration of GRI-0803 Inhibited Lupus Nephritis and Significantly Improved Overall Survival in Animal Models (GlobeNewswire)
Aug-03-23 08:30AM	GRI Bio (NASDAQ: GRI) to Present at Benzingas Virtual Biotech Conference (GlobeNewswire)
Jul-26-23 11:15AM	JTC Team to Host Two Virtual Investor Spotlight Events on Thursday, July 27th (ACCESSWIRE)
Jul-24-23 09:00AM	GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor The GRI Opportunity Spotlight Event (GlobeNewswire)
Jul-05-23 08:45AM	GRI Bio, Inc. (NASDAQ: GRI) to Participate in the Virtual Investor Summer Spotlight Series (GlobeNewswire)
Jun-27-23 08:45AM	GRI Bio (NASDAQ: GRI) Bolsters Patent Portfolio (GlobeNewswire)
Jun-15-23 08:45AM	GRI Bio (NASDAQ: GRI) to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest (GlobeNewswire) -7.41%
Jun-13-23 08:35AM	GRI Bio (NASDAQ: GRI) Announces Corporate Rebranding and Launch of New Website (GlobeNewswire)
May-22-23 08:45AM	GRI Bio (NASDAQ: GRI) Provides Business Outlook and Highlights Upcoming Milestones for Innovative Pipeline of NKT Cell Modulators (GlobeNewswire)
Apr-27-23 09:05AM	GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor New to the Street Event (GlobeNewswire) +17.98%
Apr-25-23 08:45AM	GRI Bio (NASDAQ: GRI) Announces Appointment of Leanne Kelly as Chief Financial Officer (GlobeNewswire) -5.53%

GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded in May 2009 and is headquartered in La Jolla, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GRI

GRI Bio Inc

Upgrade your FINVIZ experience